EXANE DERIVATIVES - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 328 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q2 2022$225,000
-93.7%
3
-93.5%
0.00%
-100.0%
Q1 2022$3,593,000
-31.2%
46
-20.7%
0.00%0.0%
Q4 2021$5,223,000
-87.4%
58
-87.1%
0.00%
-90.0%
Q3 2021$41,615,000
+10.2%
450
-17.4%
0.01%
+11.1%
Q2 2021$37,757,000
-7.0%
5450.0%0.01%
-25.0%
Q1 2021$40,617,000
-62.5%
545
-14.3%
0.01%
-62.5%
Q4 2020$108,427,000
+21.4%
6360.0%0.03%
+23.1%
Q3 2020$89,309,000
-12.4%
6360.0%0.03%
-3.7%
Q2 2020$101,969,000
+63.9%
6360.0%0.03%
+58.8%
Q1 2020$62,211,000
-76.4%
636
-68.6%
0.02%
-65.3%
Q4 2019$263,390,000
+72.9%
2,0230.0%0.05%
+81.5%
Q3 2019$152,343,000
-50.4%
2,0230.0%0.03%
-50.0%
Q2 2019$307,277,000
+27.5%
2,0230.0%0.05%
+12.5%
Q1 2019$241,028,000
+27.1%
2,023
+16.4%
0.05%
+41.2%
Q4 2018$189,609,000
-16.1%
1,738
+24.1%
0.03%
-19.0%
Q3 2018$226,029,000
+22.2%
1,4000.0%0.04%
+35.5%
Q2 2018$184,974,0001,4000.03%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Perceptive Advisors 2,878,979$69,182,0007.27%
Eventide Asset Management 259,100$6,226,0000.97%
GLADE BROOK CAPITAL PARTNERS LLC 251,000$6,032,0000.93%
IMS Capital Management 32,215$774,0000.91%
Perceptive Advisors 350,000$8,413,0000.88%
Benchmark Capital Advisors 34,900$839,0000.58%
BECK CAPITAL MANAGEMENT, LLC 24,744$636,0000.49%
SABBY MANAGEMENT, LLC 352,100$8,461,0000.47%
Hatteras Alternative Mutual Funds, LLC 39,404$947,0000.46%
Potomac Capital Management, Inc. 22,100$531,0000.45%
View complete list of SAREPTA THERAPEUTICS INC shareholders